Skip to main content

Table 4 Resistance of gedatolisib in SW620/GEDA could be reversed by knockdown of ABCB1 and/or ABCG2

From: ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells

Drug IC50 ± SD
SW620/GEDA (μΜ)
Gedatolisib 6.017 ± 0.815
+ control-siRNA 6.124 ± 0.588
+ ABCB1-siRNA 3.102 ± 0.426*
+ ABCG2-siRNA 2.053 ± 0.301*
+ ABCB1-siRNA
+ ABCG2-siRNA
0.526 ± 0.078*
Doxorubicin 0.428 ± 0.051
+ control-siRNA 0.461 ± 0.059
+ ABCB1-siRNA 0.103 ± 0.011*
Paclitaxel 0.891 ± 0.093
+ control-siRNA 0.879 ± 0.077
+ ABCB1-siRNA 0.305 ± 0.042*
Mitoxantrone 0.936 ± 0.097
+ control-siRNA 0.925 ± 0.089
+ ABCG2-siRNA 0.136 ± 0.021*
Topotecan 2.905 ± 0.221
+ control-siRNA 2.798 ± 0.235
+ ABCG2-siRNA 0.217 ± 0.027*
  1. *Presents when p value is < 0.05. Data was showed with mean ± SD, which is representative for at least three independent experiments